Why the study?
Does picropodophyllin inhibit growth and cause tumor regression in glioblastoma models?
Does picropodophyllin inhibit growth and cause tumor regression in glioblastoma models?
Picropodophyllin demonstrates efficacy in inhibiting glioblastoma cell growth and causing tumor regression in vivo, including crossing the blood-brain barrier.
Supports PPP evaluation in glioblastoma trials; animal data leave open clinical translation and safety.
Glioblastoma (GB) is the most common malignant brain tumor in adults. It has limited treatment opportunities and is almost exclusively fatal. Owing to the central role the insulin-like growth factor-1 receptor (IGF-1R) plays in malignant cells, it has been suggested as a target for anticancer therapy including GB. The cyclolignan picropodophyllin (PPP) inhibits IGF-1R without affecting the highly homologous insulin receptor. Here, we show that PPP inhibits growth of human GB cell lines along with reduced phosphorylation of IGF-1R and AKT. In vivo, PPP-treatment causes dramatic tumor regression not only in subcutaneous xenografts but also in intracerebral xenografts, indicating passage of PPP across the blood-brain barrier.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: